ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX – Get Free Report) has earned an average rating of “Moderate Buy” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $35.00.
A number of equities research analysts have recently weighed in on ADRX shares. Morgan Stanley assumed coverage on ADARx Pharmaceuticals in a research note on Tuesday, October 20th. They set an “overweight” rating and a $32.00 price target on the stock. Zacks Research upgraded shares of ADARx Pharmaceuticals to a “hold” rating in a report on Wednesday, October 21st. UBS Group started coverage on shares of ADARx Pharmaceuticals in a research report on Tuesday, October 20th. They issued a “buy” rating and a $35.00 price objective for the company. TD Cowen initiated coverage on shares of ADARx Pharmaceuticals in a research report on Tuesday, October 20th. They issued a “buy” rating for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of ADARx Pharmaceuticals in a research note on Tuesday, October 20th. They issued an “overweight” rating and a $38.00 target price for the company.
Read Our Latest Analysis on ADARx Pharmaceuticals
Insider Buying and Selling at ADARx Pharmaceuticals
In related news, Director Simeon George purchased 1,600,000 shares of the firm’s stock in a transaction on Monday, September 28th. The stock was acquired at an average price of $17.00 per share, with a total value of $27,200,000.00. Following the completion of the acquisition, the director owned 5,554,094 shares in the company, valued at approximately $94,419,598. This represents a 40.46% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Sr One Capital Management, Llc purchased 1,600,000 shares of the firm’s stock in a transaction on Monday, September 28th. The stock was bought at an average cost of $17.00 per share, with a total value of $27,200,000.00. Following the acquisition, the insider owned 5,554,094 shares of the company’s stock, valued at approximately $94,419,598. The trade was a 40.46% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 3,261,516 shares of company stock worth $55,445,772.
Institutional Investors Weigh In On ADARx Pharmaceuticals
A hedge fund recently bought a new stake in ADARx Pharmaceuticals stock. Goldman Sachs Group Inc. bought a new stake in ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 181,300 shares of the company’s stock, valued at approximately $3,615,000. Goldman Sachs Group Inc. owned 0.17% of ADARx Pharmaceuticals at the end of the most recent reporting period.
ADARx Pharmaceuticals Trading Down 1.4%
Shares of ADRX stock opened at $14.00 on Tuesday. ADARx Pharmaceuticals has a 1-year low of $12.50 and a 1-year high of $23.21.
ADARx Pharmaceuticals (NASDAQ:ADRX – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($1.34). On average, analysts forecast that ADARx Pharmaceuticals will post -2.03 earnings per share for the current year.
About ADARx Pharmaceuticals
ADARx Pharmaceuticals is a clinical-stage biopharmaceutical company developing RNA-targeted medicines for serious diseases. Its research focuses on oligonucleotide therapeutics designed to alter the activity of specific RNA molecules and, in turn, address disease-related gene expression. The company’s pipeline includes investigational candidates for conditions such as hereditary angioedema and complement-mediated diseases. These therapies remain in development and have not been established as approved treatments.
Featured Stories
- Five stocks we like better than ADARx Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for ADARx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADARx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
